Reg FD Disclosure

Securities and Exchange Commission, the information in this Item 7.01 disclosure, including Exhibit 99.1 and information set forth therein, is deemed to have been furnished and shall not be deemed to be “filed” under the Securities Exchange Act of 1934, as amended.   Item 9.01 Financial Statements and Exhibits.   (d) Exhibits.   Exhibit Number   Description       99.1   Letter to Stockholders, dated January 9, 2023.       104   Cover Page Interactive Date File (the cover page XBRL tags are embedded within the inline XBRL document).         SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   Date: January 9, 2023     PROVECTUS BIOPHARMACEUTICALS, INC.         By: /s/ Heather Raines                              Heather Raines, CPA     Chief Financial Officer (Principal Financial Officer)